Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Raymond James Financial to Strong-Buy Rating

Dianthus Therapeutics (NASDAQ:DNTH) was upgraded by equities researchers at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a $123.00 price target on the stock, up from their previous price target of $63.00. Raymond James Financial’s price target indicates a potential upside of 55.24% from the stock’s previous close.

Other research analysts have also issued reports about the company. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday. Oppenheimer boosted their price objective on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research report on Monday. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday. HC Wainwright upped their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $115.33.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $79.23 on Tuesday. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $84.86. The firm has a market cap of $3.42 billion, a PE ratio of -22.77 and a beta of 1.56. The business’s 50 day simple moving average is $49.17 and its 200 day simple moving average is $41.17.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its stake in shares of Dianthus Therapeutics by 3,366.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 88.2% during the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. State Street Corp raised its stake in shares of Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after buying an additional 836,571 shares during the period. Braidwell LP bought a new position in shares of Dianthus Therapeutics during the 3rd quarter worth $32,859,000. Finally, Polar Capital Holdings Plc bought a new stake in Dianthus Therapeutics in the 3rd quarter valued at about $29,434,000. 47.53% of the stock is owned by institutional investors.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision for the Phase 3 CAPTIVATE CIDP trial — the company reported it met the Part A responder criteria (20 confirmed responders with fewer than 40 completers) and will keep the 300mg S.C. dose while engaging regulators to remove the 600mg dose, accelerating the program toward the planned next steps. Early GO Decision Press Release
• Positive Sentiment: Multiple analyst upgrades and higher price targets have lifted sentiment and helped push DNTH to a new 12‑month high; this analyst momentum supports further upside expectations. Analyst Upgrade / 12-Month High
• Neutral Sentiment: Company hosted / scheduled a conference call and webcast to discuss the interim responder analysis (transcript and slides available) — useful for investors seeking detail on responder definitions and next steps but not new data beyond the GO decision. Conference Call / Webcast Notice
• Neutral Sentiment: Short interest data reported appears negligible/zero and does not presently signal a material short pressure or squeeze dynamic. (Entry data showed 0 shares short, 0.0 days to cover.)
• Negative Sentiment: Proposed $400 million underwritten public offering — the company announced a sizable equity raise (with a 30‑day option to upsize by $60M), which can be dilutive and likely caps near‑term upside until proceeds are deployed. Public Offering Announcement
• Negative Sentiment: Q4 earnings miss — DNTH reported a larger-than-expected GAAP loss (EPS -$1.43 vs. consensus -$0.97); while revenue beat nominally, the wider loss underscores current cash burn and execution risks. Q4 Results / Earnings Miss
• Negative Sentiment: New AI/cyber/privacy risk disclosure — the company flagged heightened cyber, privacy and reputational risks related to AI integration, a cautionary corporate‑governance/regulatory risk that could increase compliance costs or negative headlines. AI / Cyber Risk Disclosure

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.